AVNT vs MTRN

Avient Corporation exhibits a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score to confirm safety from distress. While profitability metrics and recent earnings surprises are positive, declining revenue and earnings growth, coupled with a high payout ratio and elevated valuation, constrain long-term appeal. The stock trades above both the Graham Number ($26.67) and intrinsic value estimate ($8.54), suggesting overvaluation on defensive and growth criteria. However, strong short-term price momentum and analyst consensus of 'strong_buy' provide counterbalancing support.

MTRN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a robust current ratio of 3.11, indicating operational stability. However, the stock is trading at a severe premium, with a current price of $172.54 far exceeding both the Graham Number ($61.21) and the growth-based intrinsic value ($25.62). While the earnings track record is exemplary with consistent beats over 25 quarters, the combination of a high P/E (47.14) and aggressive insider selling by the CEO and CFO suggests the stock may be overextended.